Protalix Wins FDA Approval for Its First Drug on the Market

Protalix BioTherapeutics Inc. jumped as much as 27 percent in extended trading after the drugmaker won approval for its debut medicine, a treatment it developed with Pfizer Inc. for a rare genetic disorder.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.